Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor–κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton

Giannis Mountzios Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, GreeceCorrespondence[email protected] [email protected]

Meletios-Athanassios Dimopoulos Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece

Aristotelis Bamias Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece

George Papadopoulos Department of Medical Oncology, 251 General Airforce Hospital, Athens, Greece

Efstathios Kastritis Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece

Konstantinos Syrigos Department of Medical Oncology, “Sotiria” University Hospital, Athens, Greece

George Pavlakis Department of Medical Oncology, 251 General Airforce Hospital, Athens, Greece

Evangelos Terpos Department of Medical Research, 251 General Airforce Hospital, Athens, Greece; Faculty of Medicine Imperial College London, London, UK

show all

Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor–κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor–κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date